Cargando…

The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis

BACKGROUND: Nafamostat mesilate decreases the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). However, no studies have administered nafamostat mesilate after ERCP. So we investigated if the infusion of nafamostat mesilate after ERCP can affect the post-ERCP pan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Joo Seong, Lee, Sang Hyub, Park, Namyoung, Huh, Gunn, Chun, Jung Won, Choi, Jin Ho, Cho, In Rae, Paik, Woo Hyun, Ryu, Ji Kon, Kim, Yong-Tae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153157/ https://www.ncbi.nlm.nih.gov/pubmed/35641898 http://dx.doi.org/10.1186/s12876-022-02345-3

Ejemplares similares

Combinatorial Effect of Prophylactic Interventions for Post-ERCP Pancreatitis among Patients with Risk Factors: A Network Meta-Analysis
por: Choi, Jin Ho, et al.
Publicado: (2023)

Cardiac arrest caused by nafamostat mesilate
por: Kim, Hyo Shik, et al.
Publicado: (2016)

Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach
por: Chun, Jung Won, et al.
Publicado: (2021)

Use of Nafamostat Mesilate as an Anticoagulant during Extracorporeal Membrane Oxygenation
por: Han, Sang Jin, et al.
Publicado: (2011)

Utility and safety of nafamostat mesilate for anticoagulation in dogs
por: Isayama, Noriko, et al.
Publicado: (2022)

High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin
por: Huh, Gunn, et al.
Publicado: (2020)

Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer
por: Uwagawa, Tadashi, et al.
Publicado: (2022)

Validation of Nafamostat Mesilate as an Anticoagulant in Extracorporeal Membrane Oxygenation: A Large-Animal Experiment
por: Han, Sung Joon, et al.
Publicado: (2018)

Optimal timing of endoscopic retrograde cholangiopancreatography for acute cholangitis associated with distal malignant biliary obstruction
por: Park, Namyoung, et al.
Publicado: (2021)

Adverse events in endoscopic retrograde cholangiopancreaticography (ERCP): Focus on post‐ERCP‐pancreatitis
por: Hollenbach, Marcus, et al.
Publicado: (2022)

Early ERCP in Biliary Pancreatitis?
por: Finch, Margaret D., et al.
Publicado: (1998)

Prevention of Post-ERCP Pancreatitis
por: Donnellan, F., et al.
Publicado: (2012)

The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation
por: Lee, Jae Ha, et al.
Publicado: (2022)

Nafamostat Mesilate: Can It Be Used as a Conduit Preserving Agent in Coronary Artery Bypass Surgery?
por: Yoon, Yoo Sang, et al.
Publicado: (2013)

Cardiac arrest caused by nafamostat mesilate: Kounis syndrome in the dialysis room?
por: Koniari, Ioanna, et al.
Publicado: (2017)

Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance
por: Kitaura, Atsuhiro, et al.
Publicado: (2023)

Nafamostat mesilate promotes endothelium-dependent vasorelaxation via the Akt-eNOS dependent pathway
por: Choi, Sujeong, et al.
Publicado: (2016)

Nonradiation-to-endoscopist ERCP is non-inferior to standard ERCP
por: Zeng, Wei, et al.
Publicado: (2021)

The future of ERCP
por: Kozarek, Richard A.
Publicado: (2017)

Somatostatin administration prior to ERCP is effective in reducing the risk of post-ERCP pancreatitis in high-risk patients
por: ZHAO, LI-NA, et al.
Publicado: (2014)

A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma
por: Chun, Jung Won, et al.
Publicado: (2022)

ERCP in Evaluating The Mode of Therapy in Pancreatic Pseudocyst
por: Nordback, I., et al.
Publicado: (1988)

Is ESR Important for Predicting Post-ERCP Pancreatitis?
por: Mohammad Alizadeh, Amir Houshang, et al.
Publicado: (2015)

ERCP-associated infected intrahepatic pancreatic pseudocyst
por: Angsubhakorn, Natthapon, et al.
Publicado: (2019)

Roles of ERCP in the Early Diagnosis of Pancreatic Cancer
por: Hanada, Keiji, et al.
Publicado: (2019)

Prognosis and risk factors of ERCP pancreatitis in elderly
por: Ergin, Erhan, et al.
Publicado: (2021)

Post-ERCP Pancreatitis: Prevention, Diagnosis and Management
por: Cahyadi, Oscar, et al.
Publicado: (2022)

Three-hour post-ERCP amylase level: a useful indicator for early prediction of post-ERCP pancreatitis
por: Lv, Ze-Hui, et al.
Publicado: (2020)

EUS and ERCP partnership
por: Binda, Cecilia, et al.
Publicado: (2021)

Nafamostat Mesilate Inhibits TNF-α-Induced Vascular Endothelial Cell Dysfunction by Inhibiting Reactive Oxygen Species Production
por: Kang, Min-Woong, et al.
Publicado: (2015)

Comparison between nafamostat mesilate and unfractionated heparin as anticoagulant during continuous renal replacement therapy
por: Makino, S, et al.
Publicado: (2015)

Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells
por: Sugano, Hiroshi, et al.
Publicado: (2018)

Prevention of post-ERCP pancreatitis: NSAID or pancreatic stent or both?
por: van Wanrooij, R. L. J., et al.
Publicado: (2019)

Is Post-ERCP Pancreatitis a Genetically Predisposed Complication?
por: Mystakidis, Konstantinos, et al.
Publicado: (2012)

Post-ERCP acute pancreatitis and its risk factors
por: Iorgulescu, A, et al.
Publicado: (2013)

UK wide survey on the prevention of post-ERCP pancreatitis
por: Hanna, Mina S, et al.
Publicado: (2014)

Reduced risk of post ERCP pancreatitis in statin users
por: Hadi, Yousaf Bashir, et al.
Publicado: (2020)

Role of ERCP in acute biliary pancreatitis: yet unanswered
por: Birda, Chhagan Lal, et al.
Publicado: (2021)

A Study of 122 Cases of Pancreatic Cancer Diagnosed by Endoscopic Retrograde Cholangiopancreatography(ERCP)
por: Moon, Young Myoung, et al.
Publicado: (1986)

Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial
por: Choi, Ji-Young, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_p7nhccvnsp4kqi1hhlrh1gr3o9